HC Wainwright Reaffirms “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 345.93% from the stock’s current price.

A number of other equities research analysts have also weighed in on HOTH. Benchmark restated a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a report on Friday, October 11th. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st.

Hoth Therapeutics Trading Up 0.8 %

NASDAQ:HOTH opened at $0.90 on Monday. Hoth Therapeutics has a 12-month low of $0.58 and a 12-month high of $1.73. The firm has a market cap of $6.19 million, a PE ratio of -0.56 and a beta of 0.84. The stock has a fifty day moving average price of $0.89 and a 200 day moving average price of $0.94.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.15. Equities analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.